Principal Scientist

Antibody Engineering

Posted on 4/18/2024

Hexagon Bio

Hexagon Bio

51-200 employees

Develops targeted therapeutics from fungal genomes

Data & Analytics


Menlo Park, CA, USA

  • PhD in Biochemistry, Bioengineering, Biophysics, Structural Biology, or related disciplines with at least 5-8 years of experience in the biotech and/or pharma industry.
  • Extensive hands-on experience with therapeutic antibody discovery and engineering.
  • Extensive hands-on laboratory experience in all aspects of antibody expression, purification, and characterization (e.g. HPLC, IEX, LCMS).
  • Experience with biological assays (multicolor flow cytometry, microscopy, ELISA) and analytical approaches (e.g. Octet/SPR, HIC) for antibody and ADC characterization.
  • Experience working with Contract Development Manufacturing Organizations (CDMOs) is a plus.
  • Ability to tackle complex scientific problems in a cross-functional environment.
  • Effective communication and ability to coordinate tasks across multiple projects as part of a multidisciplinary research team.
  • Proven ability to coach and manage a team.
  • Initiative and boldness to dive into a fast-paced new startup.
  • Lead antibody engineering, production and analytical efforts to develop novel therapeutic ADCs.
  • Produce engineered antibodies through mammalian expression and purification.
  • Perform in vitro cell-handling experiments, such as cell transfection, and cell transduction.
  • Perform antibody characterization using biological (multicolor flow cytometry, ADCC/CDC assays, ELISA, and imaging) and analytical methods (Octet/SPR, HPLC, SEC, IEX, mass spectrometry, endotoxin detection).
  • Work closely with biologists, protein engineers and chemists to advance antibody drug conjugates.
  • Analyze and interpret data, and effectively communicate findings to multi-disciplinary teams.

Hexagon Bio develops targeted small molecule therapeutics using a proprietary platform that combines data science, genomics, synthetic biology, chemistry, and automation. The company mines fungal genomes to discover potent small molecules and their targets for the next generation of targeted therapies, including next-generation antibody drug conjugate (ADC) payloads for cancer.

Company Stage

Series B

Total Funding



Menlo Park, California



Growth & Insights

6 month growth


1 year growth


2 year growth